Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

Inclusion Criteria: * Diagnosis of an interstitial lung disease (usual interstitial pneumonia \[UIP\], nonspecific interstitial pneumonia \[NSIP\] or sarcoidosis) with high resolution CT and a total lung capacity (TLC) ≤ 90% or scleroderma associated pulmonary arterial hypertension (PAH) with total lung capacity (TLC) ≤ 80%. * Interstitial lung disease (ILD) must have been stable for at least 3 months (decrease in forced vital capacity (FVC)\< 10% and diffusing capacity of lung for carbon monoxide (DLco) \< 15 % in 3 months), i.e. no significant changes in pulmonary function testing and stable medication in terms of ILD (e.g., corticosteroids, immunosuppressants) * Mean pulmonary vascular resistance (PVR) \> 400 dyne sec cm-5 or mean pulmonary arterial pressure (PAP mean) \> 30 mmHg * Pulmonary capillary wedge pressure (PCWP) \< 15 mmHg * Hemodynamic parameters at baseline (PAP, PCWP, cardiac output \[CO\], systemic mean arterial pressure \[SAP\]) * High resolution computer tomography (HRCT) (should not be older than 12 months prior start of the study) * Heart rate \> 55 beats per minute (BPM) and \< 105 BPM at rest * Systolic blood pressure (SBP) \> 90 mmHg * World Health Organisation (WHO) functional class II, III and IV * 6 Minute Walking Test (6MWT) \> 100m and \< 450 m * Stable controlled arterial hypertension according to current guidelines * Women of childbearing potential will be included in the study if the pregnancy test is negative and combination of condoms with …